Therapeutic | Pidilizumab |
Target | PDCD1 |
Heavy Chain | QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS |
Light Chain | EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-II |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | American Cancer Society, Beth Israel Deaconess Medical Center, CureTech, Georgia Regents University, Hadassah Medical Organization, Northwestern University, The Ohio State University Comprehensive Cancer Center, University of Texas M. D. Anderson Cancer Center |
Conditions Approved | na |
Conditions Active | Acute myeloid leukaemia, Colorectal cancer, Diffuse large B cell lymphoma, Follicular lymphoma, Malignant melanoma, Multiple myeloma, Pancreatic cancer, Prostate cancer, Renal cell carcinoma, Glioma, Hepatitis C, Liver cancer |
Conditions Discontinued | na |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]